Epitalon

Structure: A linear tetrapeptide, alanine-glutamate-aspartate-glycine. It was derived by identifying the shortest active fragment of epithalamin, a peptide preparation extracted from bovine pineal glands by Vladimir Khavinson's group at the St Petersburg Institute of Bioregulation and Gerontology. Understanding that lineage matters, because much of the human data people cite for Epitalon was actually generated with the gland extract, not the synthetic tetrapeptide.

Dosage:

• Standard course: 5-10mg per day SubQ for 10 to 20 consecutive days, repeated once or twice per year.
• Cumulative course approach: some protocols target a total of 50-100mg per course and split it across the days as convenient.
• Continuous daily use is not part of any published protocol. The design intent was always a short pulsed course.

Administration:

• SubQ, insulin syringe, abdomen. Some users inject IM; there is no evidence either route is superior.
• Reconstitute with bacteriostatic water and refrigerate.
• Oral and nasal products exist and are almost certainly pointless. A four amino acid peptide taken orally is digested into its constituent amino acids.

Key Notes:

• Be honest about the evidence, because the marketing is not. The telomerase claim rests primarily on cell culture work from Khavinson's own group showing telomerase activation and telomere elongation in human somatic cell lines. The lifespan claims rest on rodent studies from the same group. The human data most often cited is a long follow-up of elderly patients given epithalamin, reporting reduced mortality over several years.
• Those human studies have serious limitations: they are old, small, largely published in Russian-language journals or a single specialist journal, conducted by the group that developed the compound, and never independently replicated. There is no registered modern randomised controlled trial of Epitalon in humans, for any endpoint. "Shown to extend human lifespan" is not a claim the literature supports, and anyone telling you it does has not read it.
• What can be said fairly: it has a long history of use, an unremarkable acute safety record in the populations studied, and a plausible pineal/melatonin mechanism that has never been properly tested. That is a reasonable basis for personal experimentation with informed consent. It is not a basis for confidence.
• It will not show up on your bloodwork. This is worth stating plainly on a bloodwork platform: there is no marker that tracks whether Epitalon is working. If you feel better on it, that is your only readout, and it is not distinguishable from placebo without a trial nobody has run.
• Telomere length testing sold direct to consumers is not a solution to this. Assay variability between draws is large relative to the change any intervention would plausibly produce, so a before-and-after result tells you very little.
• It is not hormonal and not suppressive, so it can be run alongside TRT, a cycle, or a peptide protocol without endocrine interaction. Practically, the main risk is the injection itself: sterility and source quality of grey-market vials.

Bloodwork Monitoring:

• No compound-specific monitoring is indicated, because no reproducible effect on standard panels has been documented. Nothing here needs a special panel.
• A general baseline is still sensible if you are injecting grey-market material: ALT, AST, Creatinine and a full blood count catch injection-related infection or an unrelated problem you were unaware of.
• CRP: only useful as a general marker if you develop injection site reactions or feel unwell on a course.
• Do not let Epitalon confound your interpretation of anything else. If a marker moves during a course, look at your AAS, GH, training and diet before attributing it to a tetrapeptide with no documented lab effects.